These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 37247682)

  • 1. Network pharmacology and experiments in vivo and in vitro reveal that the Jia-Wei-Bu-Shen-Yi-Qi formula (JWBSYQF) and its active ingredient baicalein ameliorate BLM-induced lung fibrosis in mice via PI3K/Akt signaling pathway.
    Shi H; Deng L; Zhou Y; Yu H; Huang X; Chen M; Lei Y; Dong J
    J Ethnopharmacol; 2023 Oct; 315():116691. PubMed ID: 37247682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics analysis reveals suppression of IL-17 signaling pathways contributed to the therapeutic effects of Jia-Wei Bu-Shen-Yi-Qi formula in a murine asthma model.
    Qin J; Wuniqiemu T; Wei Y; Teng F; Cui J; Sun J; Yi L; Tang W; Zhu X; Xu W; Dong J
    Phytomedicine; 2022 Jan; 95():153803. PubMed ID: 34785105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESL attenuates BLM-induced IPF in mice: Dual mediation of the TLR4/NF-κB and TGF-β1/PI3K/Akt/FOXO3a pathways.
    Jia C; Yang M; Xiao G; Zeng Z; Li L; Li Y; Jiang J; Xu A; Qiu J; Tang R; Li D; Jia D; Xie C; Wu G; Cai D; Bi X
    Phytomedicine; 2024 Sep; 132():155545. PubMed ID: 38972238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the active compounds and functional mechanisms of Jinshui Huanxian formula in pulmonary fibrosis by integrating serum pharmacochemistry with network pharmacology.
    Shao D; Liu X; Wu J; Zhang A; Bai Y; Zhao P; Li J
    Phytomedicine; 2022 Jul; 102():154177. PubMed ID: 35636171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated plasma pharmacochemistry and network pharmacology to explore the mechanism of Gerberae Piloselloidis Herba in treatment of allergic asthma.
    Zhou K; Lu D; You J; Liu T; Sun J; Lu Y; Pan J; Li Y; Liu C
    J Ethnopharmacol; 2022 Nov; 298():115624. PubMed ID: 35970314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A network pharmacology approach and experimental validation to investigate the anticancer mechanism and potential active targets of ethanol extract of Wei-Tong-Xin against colorectal cancer through induction of apoptosis via PI3K/AKT signaling pathway.
    Lin F; Zhang G; Yang X; Wang M; Wang R; Wan M; Wang J; Wu B; Yan T; Jia Y
    J Ethnopharmacol; 2023 Mar; 303():115933. PubMed ID: 36403742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network pharmacology, molecular docking and experimental verification of the mechanism of huangqi-jixuecao herb pair in treatment of peritoneal fibrosis.
    Dai H; Shan Y; Yu M; Wang F; Zhou Z; Sun J; Sheng L; Huang L; Sheng M
    J Ethnopharmacol; 2024 Jan; 318(Pt A):116874. PubMed ID: 37437794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research into the anti-pulmonary fibrosis mechanism of Renshen Pingfei formula based on network pharmacology, metabolomics, and verification of AMPK/PPAR-γ pathway of active ingredients.
    Yan L; Jiang MY; Fan XS
    J Ethnopharmacol; 2023 Dec; 317():116773. PubMed ID: 37308028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated strategy of network pharmacology, molecular docking, HPLC-DAD and mice model for exploring active ingredients and pharmacological mechanisms of Penthorum chinense Pursh against alcoholic liver injury.
    Jiang Y; Zhong M; Zhan H; Tao X; Zhang Y; Mao J; Geng Z; Gao B
    J Ethnopharmacol; 2022 Nov; 298():115589. PubMed ID: 35926779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Network pharmacology-based prediction and validation of the active ingredients and potential mechanisms of the Huangxiong formula for treating ischemic stroke.
    Zhao S; Zhang P; Yan Y; Xu W; Li J; Wang L; Wang N; Huang Y
    J Ethnopharmacol; 2023 Aug; 312():116507. PubMed ID: 37080367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network Pharmacology Followed by Experimental Validation to Explore the Mechanism of Stigmasterol in Sangbaipi Decoction Regulating PI3K/Akt Signaling to Alleviate Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
    He H; Sun S; Xu W; Zhang M
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1819-1834. PubMed ID: 39140079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the comorbidity mechanisms between asthma and idiopathic pulmonary fibrosis and the pharmacological mechanisms of Bu-Shen-Yi-Qi decoction therapy via network pharmacology.
    Zhong Y; Hu L; Chen W; Wang B; Sun J; Dong J
    BMC Complement Med Ther; 2022 Jun; 22(1):151. PubMed ID: 35672815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Mechanisms of Modified Bu-Shen-Yi-Qi Decoction for COPD-Related Osteoporosis Therapy via Transcriptomics and Network Pharmacology Approach.
    Zhong Y; Wang B; Chen W; Zhang H; Sun J; Dong J
    Drug Des Devel Ther; 2023; 17():2727-2745. PubMed ID: 37701046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of network pharmacology and serum medicinal chemistry to investigate the pharmacological mechanisms of QiZhuYangGan Decoction in the treatment of hepatic fibrosis.
    Deng JW; Yuan S; Shi LP; Chen X; Liu J; Chen ZW; Tan KY; Yang Q; Cao WF
    J Ethnopharmacol; 2024 Apr; 323():117730. PubMed ID: 38190954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network pharmacology analysis, molecular docking integrated experimental verification reveal β-sitosterol as the active anti-NSCLC ingredient of Polygonatum cyrtonema Hua by suppression of PI3K/Akt/HIF-1α signaling pathway.
    Cao W; Yuan F; Liu T; Yin R
    J Ethnopharmacol; 2024 Jun; 328():117900. PubMed ID: 38432577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of the mechanism of Qinglongyi-Buguzhi drug pair in treating vitiligo based on network pharmacology, molecular docking and experimental verification.
    Chen L; Chen S; Li P; Zhao X; Sun P; Liu X; Wei H; Jiang X; Zhan Z; Wang J
    J Ethnopharmacol; 2024 Nov; 334():118595. PubMed ID: 39038503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fufang Shenhua tablet inhibits renal fibrosis by inhibiting PI3K/AKT.
    Li R; Shi C; Wei C; Wang C; Du H; Liu R; Wang X; Hong Q; Chen X
    Phytomedicine; 2023 Jul; 116():154873. PubMed ID: 37257328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schisandrol A, the main active ingredient of Schisandrae Chinensis Fructus, inhibits pulmonary fibrosis through suppression of the TGF-β signaling pathway as revealed by UPLC-Q-TOF/MS, network pharmacology and experimental verification.
    Wu Z; Jia M; Zhao W; Huang X; Yang X; Chen D; Qiaolongbatu X; Li X; Wu J; Qian F; Lou Y; Fan G
    J Ethnopharmacol; 2022 May; 289():115031. PubMed ID: 35091014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of the Bupi Yishen formula on renal fibrosis through PI3K/AKT signaling inhibition.
    Liu B; Deng J; Jie X; Lu F; Liu X; Zhang D
    J Ethnopharmacol; 2022 Jul; 293():115242. PubMed ID: 35367329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncovering the action mechanism of Shenqi Tiaoshen formula in the treatment of chronic obstructive pulmonary disease through network pharmacology, molecular docking, and experimental verification.
    Qinjun Y; Dandan Y; Hui W; Yating G; Xinheng W; Di WU; Jiabing T; Chuanbo W; Zegeng LI
    J Tradit Chin Med; 2024 Aug; 44(4):770-783. PubMed ID: 39066538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.